These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27793960)

  • 1. U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
    Singh H; Brave M; Beaver JA; Cheng J; Tang S; Zahalka E; Palmby TR; Venugopal R; Song P; Liu Q; Liu C; Yu J; Chen XH; Wang X; Wang Y; Kluetz PG; Daniels SR; Papadopoulos EJ; Sridhara R; McKee AE; Ibrahim A; Kim G; Pazdur R
    Clin Cancer Res; 2017 Jan; 23(2):330-335. PubMed ID: 27793960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
    Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.
    Viola D; Cappagli V; Elisei R
    Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
    Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
    Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
    Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
    Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
    Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
    Powles T; Motzer RJ; Escudier B; Pal S; Kollmannsberger C; Pikiel J; Gurney H; Rha SY; Park SH; Geertsen PF; Gross-Goupil M; Grande E; Suarez C; Markby DW; Arroyo A; Dean M; Choueiri TK; George D
    Br J Cancer; 2018 Sep; 119(6):663-669. PubMed ID: 30197417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
    Schmidinger M; Danesi R
    Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis.
    Xu JX; Maher VE; Zhang L; Tang S; Sridhara R; Ibrahim A; Kim G; Pazdur R
    Oncologist; 2017 Mar; 22(3):311-317. PubMed ID: 28232599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
    Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib Approved for Renal Cell Carcinoma.
    Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
    Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
    BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.